Jacqueline Lemke Named Interim President & CEO of Bioanalytical Systems

BASi (Bioanalytical Systems, Inc.)

announced today that CFO Jacqueline M. Lemke has been named to the additional posts of interim President & CEO. Ms. Lemke succeeds Anthony S. Chilton, Ph.D., who has resigned as CEO to pursue other opportunities. "Jacqueline Lemke has demonstrated exceptional skill, energy and commitment since she joined BASi as CFO three months ago. In this short time she has significantly reduced the company's cost structure, refocused our marketing program, and instituted aggressive performance goals for all operating departments. Many more changes are in the works. As interim President and CEO, with continuing responsibility as CFO, we expect Jackie to complete the transformation of BASi and deliver the growth and profitability we believe this company is capable of delivering. Board member Richard Johnson and I, with more than 60 years of combined major pharma and CRO experience, will work closely with Jackie during this interim period," said John B. Landis, Ph.D., Chairman.